DexCom (NASDAQ:DXCM) Raised to Buy at StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a buy rating in a research note released on Friday.

DXCM has been the topic of a number of other research reports. Raymond James cut their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday. BTIG Research reduced their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. Finally, Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Down 1.8 %

Shares of NASDAQ DXCM opened at $72.10 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The business has a fifty day simple moving average of $70.11 and a two-hundred day simple moving average of $97.65. The firm has a market cap of $28.67 billion, a PE ratio of 46.69, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock valued at $126,390 in the last ninety days. Insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC boosted its stake in shares of DexCom by 11.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,322 shares of the medical device company’s stock worth $3,512,000 after acquiring an additional 2,591 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of DexCom during the first quarter worth $347,000. Toth Financial Advisory Corp raised its position in shares of DexCom by 870.9% in the first quarter. Toth Financial Advisory Corp now owns 6,583 shares of the medical device company’s stock valued at $913,000 after buying an additional 5,905 shares during the last quarter. Trilogy Capital Inc. purchased a new position in shares of DexCom in the first quarter worth about $470,000. Finally, Congress Wealth Management LLC DE boosted its position in DexCom by 0.6% during the first quarter. Congress Wealth Management LLC DE now owns 168,657 shares of the medical device company’s stock worth $23,393,000 after acquiring an additional 952 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.